Rangering i aksjer
#25837
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB... Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Handel Mendus AB (publ) (IMMU)
Pris IMMU pris med markedsverdi på B
Markedsverdi av Mendus AB (publ)(IMMU)
Markedsverdi: $45.86M
Per August 2026 har Mendus AB (publ) en markedsverdi på $45.86M. Dette gjør Mendus AB (publ) til det 25837th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Mendus AB (publ) fra 2013 til 2026
IMMU sammenlignet med topp 5 mest populære stocks
| Pris på IMMU |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.257T
|
+11,462,312.92%
|
|
|
|
|
$4.599T
|
+10,027,128.07%
|
|
|
|
|
$4.107T
|
+8,954,186.11%
|
|
|
|
|
$3.577T
|
+7,799,997.77%
|
|
|
|
|
$2.807T
|
+6,121,148.29%
|
